A new positron emission tomography radiotracer enables imaging of the human glutamate receptor AMPA-R, a fundamental component of neurotransmission involved in neuropsychiatric disorders.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Miyazaki, T. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0723-9 (2020).
Malinow, R. & Malenka, R. C. Annu. Rev. Neurosci. 25, 103–126 (2002).
Pilowsky, L. S. et al. Mol. Psychiatry 11, 118–119 (2006).
Bressan, R. A. et al. Biol. Psychiatry 58, 41–46 (2005).
Ahmed, A. H., Ptak, C. P. & Oswald, R. E. Biochemistry 49, 2843–2850 (2010).
Mathern, G. W. et al. J. Neuropathol. Exp. Neurol. 57, 615–634 (1998).
Mathern, G. W. et al. Brain 120, 1937–1959 (1997).
Finnema, S. J. et al. Sci. Transl. Med. 8, 348ra96 (2016).
Lam, J. et al. Ann. Neurol. 85, 218–228 (2019).
DeLorenzo, C. et al. Biol. Psychiatry 77, 266–275 (2015).
Martin-Facklam, M. et al. Neuropsychopharmacology 38, 504–512 (2013).
J.H.K. is supported by funds from the US Department of Veterans Affairs via its support of the National Center for PTSD, by the National Institute on Alcohol Abuse and Alcoholism via its support of the Center for the Translational Neuroscience of Alcoholism (P50 AA021818), and the National Center for Advancing Translational Science (NCATS) via its support for CTSA Grant Number UL1 TR001863. J.H.K. is a co-sponsor of a patent for the intranasal administration of ketamine for the treatment of depression and for the treatment of suicide risk that was licensed by Janssen Pharmaceuticals; has a patent related to the use of riluzole to treat anxiety disorders that was licensed by Biohaven Pharmaceuticals; has stock or stock options in Biohaven Pharmaceuticals, Blackthorn Therapeutics, Luc Therapeutics, Cadent Pharmaceuticals, Terran Biosciences, Spring Healthcare, and Sage Pharmaceuticals; serves on the Board of Directors of Inheris Pharmaceuticals; leads two studies in which pharmaceutical companies (Cerevel Pharmaceuticals and Novartis) have provided access to drugs without charge; has received, over the past 3 years, over US$5,000 in compensation for consulting to Sunovion, Takeda, Novartis, and Janssen Pharmaceuticals; and receives over US$5,000 in income from the Society of Biological Psychiatry in compensation for serving as editor of the journal Biological Psychiatry.
About this article
Cite this article
Krystal, J.H. Imaging the glutamate synapse. Nat Med 26, 165–167 (2020). https://doi.org/10.1038/s41591-020-0760-4